Acute Myeloid Leukemia (AML) Treatment Market Analysis

Treatment Type [Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy), Targeted Therapy, Immunotherapy, Hormone Therapy]

Chemotherapy segment is estimated to capture over 62% acute myeloid leukemia market share by 2036. Chemotherapy is significantly utilized for the solidification treatment of acute myeloid leukemia. Owing to its effectiveness in curing AML the cytarabine is massively utilized during chemotherapy.

According to organizations working in the field of cancer, cytarabine a type of chemotherapy drug is more efficient at treating acute myeloid leukemia and that's why it gets so much use.

The growth of this market is also expected to be driven by an increase in US Food and Drug Administration approval for cytarabine as a treatment for acute myelodysplastic syndrome.

For instance, in March 2021 Jazz Pharmaceuticals plc announced that it received approval from the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos (daunorubicin and cytarabine) to add a new indication for the treatment of children patients one year of age and older with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related alterations to advance cancer research and concentrating on the individuals who can benefit from it most.

End Users (Hospitals, Homecare, Specialty Centers)

Hospital segment in the acute myeloid leukemia market is poised to grow at over 10% CAGR between 2024 and 2036. The growth can be accredited to the growing healthcare industry. Several countries across the globe are investing in the development of healthcare infrastructure, leading to improvement in cancer treatment, and diagnostic facilities through earlier detection and treatment of acute myeloid leukemia disease.

More and more hospitals around the world are being equipped with advanced facilities to provide AML patients with integrated care. In addition, screening, and treatment facilities are provided to the patients under one roof in hospitals.

For instance, by 2026, it is anticipated that the healthcare sector in India will generate more than USD 600 billion.

Disease Type (Myeloblastic, Promyelocytic, Myelomonocytic)

Myeloblastic segment is expected to dominate over 40% acute myeloid leukemia market share by 2036. This growth of the segment is set to be encouraged by the growing pediatric population. Acute myeloblastic leukemia, the second most common type of leukemia in children, is a malignant disorder where the bone marrow creates an enormous amount of abnormal blood cells and has the worst prognosis of all childhood cancers.

According to estimates, more than 20% of people on the planet are under the age of 15.

Our in-depth analysis of the market includes the following segments: